



Colorectal Cancer: From Pathophysiology to Novel Therapeutic Approaches 3.0

Guest Editor:

Dr. Valeria Barresi

Department of Diagnostics and
Public Health, P.le L.A. Scuro,
University of Verona, 37129
Verona, Italy

Deadline for manuscript
submissions:

closed (31 July 2023)

Message from the Guest Editor

Dear Colleagues,

Colorectal cancer (CRC) is one of the most common malignancies worldwide. Therapeutic approaches vary according to tumor location (colonic or rectal) and pTNM stage, the latter representing a main prognostic factor.

In spite of the improvement in the early diagnosis and therapy of CRC, several issues are still open. First, the identification of factors associated with a high risk of progression in non-metastatic (pN0M0) CRC still represents a research challenge and means it would be relevant to select patients for adjuvant treatments. Second, in view of the spreading endoscopic resection of CRC, predictors of nodal metastases in pT1 tumors would help in identifying patients needing surgery. Finally, pre-treatment clinical, endoscopic, or histological features able to predict the response of rectal adenocarcinoma to neo-adjuvant chemo-radiotherapy (CRT) would be useful to design tailored therapeutic strategies.

The aim of this Special Issue is to provide new insights into prognostic and predictive factors for early or pN0M0 CRC, and for locally advanced rectal carcinoma treated with neo-adjuvant CRT. These could be useful to develop individualized treatments.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI